Disclosed is an immunogenic composition comprising: (a) a glycan conjugate including a carrier protein, and a glycan including Globo H, an immunogenic fragment thereof, or stage-specific embryonic antigen-4 (SSEA-4), wherein the glycan is conjugated with the carrier protein through a linker； and (b) an adjuvant including C34, wherein C34 is defined in the specification. Also disclosed is the use of the immunogenic composition in the manufacture of a medicament for the treatment or inhibition of tumor growth, wherein administration of medicament induces au immune response that produces a higher relative level of IgG isotype antibodies as compared to IgM isotype antibodies.
